Affymetrix and Athletigen Partner
News Oct 29, 2015
Affymetrix Inc. and Athletigen Technologies Inc. have announced a global partnership agreement. Under the agreement, Athletigen will use Affymetrix Axiom® genotyping platform for its sports-related DNA analysis service.
DNA from a saliva sample will be genotyped using Athletigen’s DNA microarray which analyzes about 850,000 variants implicated in human athletic performance. The high quality data generated when analyzed with Athletigen’s interpretative bioinformatics algorithm enables the delivery of an online, easy-to-use, actionable report on traits relating to athleticism, nutrition, and sports psychology.
“Affymetrix’ Axiom platform offers the gold standard for genotyping analysis and, when coupled with our highly curated content selection and interpretative analysis, ensures precision and accuracy for our personalized sports genetics reports to create a blueprint for improving human athletic performance,” said Jeremy Koenig, PhD, CEO of Athletigen Technologies Inc.
“We are pleased to support Athletigen’s sports genetic offering that empowers athletes and coaches to better understand their athletic traits. Our high fidelity Axiom genotyping platform, due to its high throughput capability, industry-leading genotyping performance, and affordability, is preferred by many large scale biobank projects worldwide and by emerging consumer genomics enterprises for genetic analysis of consumer bio-specimens,” said Laurent Bellon, senior vice president and general manager of the Genotyping Business Unit of Affymetrix.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.